Nuvectis Pharma (NVCT) Cash & Equivalents (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Cash & Equivalents data on file, last reported at $25.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 16.05% year-over-year to $25.1 million; the trailing twelve-month figure through Mar 2026 stood at $25.1 million (down 16.05% YoY), and the FY2025 full-year result was $31.6 million, up 70.69% from the prior year.
• Cash & Equivalents declined to $25.1 million in Q1 2026, from $31.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $35.4 million in Q3 2025 to a low of $13.6 million in Q2 2022.
• A 5-year average of $22.3 million and a median of $20.8 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slipped 26.36% in 2024 and jumped 106.43% in 2025, its largest moves.
• Tracing NVCT's Cash & Equivalents over 5 years: stood at $23.6 million in 2022, then fell by 18.96% to $19.1 million in 2023, then declined by 3.1% to $18.5 million in 2024, then jumped by 70.69% to $31.6 million in 2025, then dropped by 20.65% to $25.1 million in 2026.
• Business Quant data shows NVCT's Cash & Equivalents at $25.1 million in Q1 2026, $31.6 million in Q4 2025, and $35.4 million in Q3 2025.